EXAMINING THE DOSING PATTERNS AND COSTS OF EPOETIN ALFA AND DARBEPOETIN ALFA AMONG HOSPITAL OUTPATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS
Author(s)
Lafeuille MH1, Naim A2, Forlenza JB2, Laliberté-Auger F1, Lefebvre P11Groupe d'analyse, Ltée, Montréal, QC, Canada, 2Janssen Scientific Affairs, LLC, Horsham, PA, USA
OBJECTIVES: To compare retrospective data of erythropoiesis-stimulating agent (ESA) dosing patterns and costs among hospital outpatients with dialysis chronic kidney disease (CKD) not on dialysis. METHODS: Electronic records from the Premier hospital database (2006Q1-2011Q1) were used to identify outpatients that had a diagnosis for CKD and received epoetin alfa (EPO) or darbepoetin alfa (DARB). Exclusion criteria were: age <18 years, receipt of renal dialysis, a diagnosis of cancer or myelodysplastic syndrome, receipt of chemotherapy, or receipt of both ESAs. The observation period consisted of the outpatient continuous ESA episode, defined as the period from first to last outpatient visit with ESA use without a gap of more than one calendar month between ESA visits. The ESA dose ratio (Units EPO: mcg DARB) was calculated using the mean cumulative dose of EPO and DARB. Treatment costs for both ESA groups were determined using cumulative dose and published July 2011 wholesale acquisition costs. RESULTS: A total of 9770 outpatient ESA episodes (EPO: 5398; DARB: 4,72) were identified. EPO and DARB groups had a similar mean age (73.1 vs. 73.5 years, respectively; P=0.104) and similar proportion of females (59.4% vs. 59.0%, respectively; P<0.663). EPO group had a longer duration of outpatient episode (3.8 months vs. 3.4 months, P<0.001) than the DARB group. The mean cumulative dose was EPO 174,010 Units and DARB 622 mcg, which resulted in a dose ratio (Units EPO: mcg DARB) of 280:1. Corresponding mean ESA treatment costs were higher for DARB than for EPO (EPO: $2,819 vs. DARB: $3,484, P<0.001). CONCLUSIONS: In this analysis of non-dialysis CKD hospital outpatient records, a dose ratio (Units EPO: mcg DARB) of 280:1 was observed. Mean ESA treatment costs were found to be approximately 24% higher for the DARB group as compared to the EPO group.
Conference/Value in Health Info
2012-06, ISPOR 2012, Washington, D.C., USA
Value in Health, Vol. 15, No. 4 (June 2012)
Code
PUK11
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Urinary/Kidney Disorders